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ABSTRACT 
 
Objective: To determine  the incidence of Diabetes Mellitus (DM) among HIV patients in the 
D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) cohort, to identify 
demographic, HIV-related and combination antiretroviral therapy (cART)-related factors 
associated with the onset of DM, and to identify possible mechanisms for any relationships 
found. 
 
Research Design and Methods: D:A:D is a prospective observational study of 33,389 HIV 
patients; DM is a study endpoint. Poisson regression models assessed the relation between 
DM and exposure to cART after adjusting for known risk factors for DM ,CD4 count, lipids 
and lipodystrophy. 
 
Results: Over 130,151 person-years of follow-up, 744 patients were diagnosed with DM 
(incidence rate of 5.72 per 1,000 PYFU (95% CI: 5.31-6.13)). The incidence of DM 
increased with cumulative exposure to cART , association that remained significant after 
adjustment for potential risk factors for DM. The strongest relationship with DM was 
exposure to stavudine; exposure to zidovudine and didanosine were also associated with an 
increased risk of DM. Time-updated measurements of total cholesterol, HDL-cholesterol and 
triglycerides were all associated with DM. Adjusting for each of these variables separately 
reduced slightly the relationship between cART and DM. While lipodystrophy was 
significantly associated with DM, adjustment for this did not modify the relationship between 
cART and DM. 
 
Conclusion: Stavudine and zidovudine are significantly associated with DM after adjustment 
for risk factors for DM and lipids. Adjustment for lipodystrophy did not modify the 
relationship, suggesting the two thymidine analogues probably directly contribute to insulin 
resistance potentially through mitochondrial toxicity. 
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ortality and morbidity from HIV 
and its complications have 
dramatically declined since the 
advent of combination anti-retroviral 
therapy (c-ART). However, metabolic 
disorders have emerged - impaired glucose 
tolerance and diabetes, as well as lipid 
disorders -  leading to an increase of  
cardiovascular disease. 
Data from the D:A:D (Data Collection 
on Adverse Events of Anti-HIV Drugs) 
Study suggest that the risk of a myocardial 
infarction is more than doubled among HIV 
patients  with Diabetes Mellitus (DM) (1). I 
Insulin resistance among treated HIV-
infected patients is  multifactorial:  in 
addition to the common contributors to 
insulin resistance (e.g. obesity, genetic 
influences, physical inactivity), 
antiretroviral drugs  and lipodystrophy 
(which may be a consequence of treatment, 
particularly with thymidine analogues), are 
involved. 
The aims of this  analysis were to 
estimate  the incidence of new onset DM 
among patients with no history of DM at 
entry to D:A:D, to identify demographic, 
HIV-related and  cART -related factors that 
were associated with the onset of DM, and 
to identify possible mechanisms for any 
relationships found. 
 
RESEARCH DESIGN AND METHODS 
The D:A:D study is a large, prospective 
observational study formed by the 
collaboration of 11  cohorts of HIV-infected 
patients. The primary aim of the study was 
to establish whether an association exists 
between the use of cART and an increased 
risk of  CVD. The 11 cohorts currently 
contribute data on 33,389 HIV-positive 
patients followed at 212 clinics in Europe, 
the US, Argentina and Australia. The D:A:D 
study methodology has been described in 
detail  (1).   Patients eligible for inclusion 
were all being actively followed up at the 
time of initiation of the D:A:D protocol , 
irrespective of antiretroviral treatment 
status.  Patients were followed 
prospectively, and data were obtained 
during visits  scheduled as part of regular 
medical care. Patient follow-up started 
between December 1999 and April 2001 
(D:A:D Phase I) and April 2001 and 
January 2005 (D:A:D Phase II). At 
enrolment, and at least every 8 months 
thereafter, standardized data collection 
forms were completed,  including socio-
demographic characteristics, clinical data 
(AIDS events and known risk factors for 
CVD), laboratory markers (CD4 cell counts, 
HIV RNA load, and total cholesterol, HDL-
cholesterol and triglyceride levels), and 
treatment variables (antiretroviral treatment 
and drugs modifying lipid levels or risk of 
CVD).  Use of ritonavir  includes both full 
and boosting doses. Data are transformed 
into a standardized format,  transferred to 
the coordinating center (Copenhagen HIV 
Programme, Hvidovre Hospital, Denmark) 
as anonymised computerized files,  and 
merged into a central dataset. 
Endpoint definition. DM has been collected 
as a secondary D:A:D endpoint . All 
prospectively documented cases of DM 
were verified  by the submission of a D:A:D 
event monitoring case report form. New 
onset DM was defined as either  definite 
diagnosis  if  fasting plasma glucose 
>7.0 mmol/L (126 mg/dl) was measured on 
two consecutive occasions, or  possible 
diagnosis  in case of physician reported date 
of DM onset and  initiation  of anti-diabetic 
therapy. 
Statistical methods. The rate of new onset 
DM  was defined as the number of cases of 
DM divided by the total person-years of 
follow-up (PYFU)). PYFU were counted in 
a similar way to the primary analyses of the 
D:A:D Study (1) from the date of enrolment  
to the date of a first diagnosis of DM, death, 
1st February 2006 or six months after the 
patient’s last clinic visit, whichever 
occurred first. Factors associated with new 
onset DM were identified using Poisson 
regression models. We  assessed the 
univariable relationships between duration 
of exposure to cART (defined  as any  
M 
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combination including a PI and/or non-
nucleoside reverse transcriptase inhibitor 
[NNRTI]) and the rate of new onset DM. 
We then investigated whether any identified 
relationship applied to all  drugs similarly, 
or whether it varied according to the type of 
antiretroviral drug received.  These analyses 
were then adjusted to take account of  
possible demographic and clinical risk 
factors for DM, including age (fitted as a 
time-updated covariate ), gender , 
transmission group (homosexual, injecting 
drug use, heterosexual, other/not known), 
race (white, black, other, not known), body 
mass index (BMI, categorized as <18, 18-
26, 26.1-30 and >30 kg/m2), smoking status 
(current, ex-, never and not known),  
patient’s nadir CD4 count, duration of HIV 
infection prior to enrolment in D:A:D and 
calendar year.  We further adjusted the 
analyses to take account of changes in lipids  
(total cholesterol, HDL-cholesterol and 
log2-transformed triglycerides) and  
development of fat loss (lipoatrophy) or fat 
gain (lipohypertrophy) . Each of these 
variables was included as a time-updated 
covariate in a separate multivariable model 
with treatment exposure and other 
demographic/clinical risk factors. All 
analyses were adjusted for cohort. 
 
RESULTS 
Overall, 952 of the 33,389 patients in 
D:A:D had a diagnosis of DM at entry to the 
study, giving a baseline prevalence of 
2.85% (95% confidence interval [CI]: 2.67-
3.03). The characteristics of the remaining 
32,437 patients are shown in Table 1. In 
these patients, over 130,151 PYFU, 744 
patients were diagnosed with DM incidence 
of 5.72 per 1,000 PYFU (95% CI: 5.31-
6.13)-  474 (63.7%) being  definite and 270 
(36.3%)  possible diagnoses. 
The incidence of new onset DM 
increased with cumulative exposure to 
cART (Figure 1(i)).  This  was significant in 
univariable analyses (unadjusted relative 
rate per year of exposure to cART: 1.06 
[95% CI 1.03-1.09], p=0.0001), and  after 
adjustment for other potential risk factors 
for DM (1.11 [1.07-1.15]; p=0.0001).   
When analyzing  whether the 
relationship with drug exposure was similar 
for all antiretroviral drugs, several findings 
emerged (Table 2). The strongest 
relationship with new onset DM was with 
exposure to stavudine (adjusted RR per year 
of exposure: 1.19 [1.15-1.24]; p=0.0001, 
unadjusted rates  are shown in Figure 1(ii)).  
Whilst exposure to zidovudine and 
didanosine were also associated with an 
increased risk of new onset DM, exposure to 
ritonavir and nevirapine were both 
associated with a reduced risk .  No other  
antiretroviral drug was significantly 
associated with the incidence of DM after 
adjusting for exposure to these drugs.  Other 
demographic and clinical factors associated 
with  increased risk of new onset DM  were 
older age, male sex, greater BMI, 
heterosexual or IDU risk group, black 
African and other ethnicities and earlier 
calendar year.  Current cigarette smoking 
was associated with a reduced risk .  After 
adjusting for these factors, there were only 
weak and non-significant relationships 
between new onset DM and the patient’s 
nadir CD4 count (RR per 50 cells/mm3 
higher: 0.98 [0.96-1.00]; p=0.06) and 
duration of HIV infection at enrolment in 
D:A:D (RR per additional year: 0.98 [0.96-
1.00]; p=0.09).   
In a series of multivariable analyses 
adjusted for these demographic and clinical 
factors as well as exposure to the five drugs, 
time-updated total cholesterol, HDL-
cholesterol and lipodystrophy  - either 
peripheral loss or central fat gain - were  
associated with new onset DM.  A one 
mmol/L higher total cholesterol level was 
associated with a 9% increased rate of DM 
(RR: 1.09 [1.03-1.15]; p=0.001), a one 
mmol/L higher HDL-cholesterol  with a 
49% reduction in the rate of DM (0.51 
[0.40-0.66]; p=0.0001), a two-fold higher 
triglyceride level  with an 81% increase in 
DM rate (1.81 [1.67-1.95]; p=0.0001) and 
fat loss or fat gain  with 28% and 57% 
increases in the risk of DM respectively 
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(1.28 [1.04-1.57]; p=0.02 and 1.57 [1.28-
1.92]; p=0.0001).  Whilst it was not possible 
to fit models that included both total 
cholesterol and triglycerides, due to the 
correlation between the two, models that 
included fat loss/gain as well as HDL 
cholesterol and triglycerides (Table 3), 
confirmed that HDL cholesterol (0.75 per 
mmol/L higher [0.58-0.96]; p=0.02), 
triglycerides (1.64 per two-fold higher 
[1.50-1.80]; p=0.0001) and fat gain (1.36 
[1.09-1.68]; p=0.006) (but not fat loss) were 
all independently associated with new onset 
DM. Adjustment for these variables did not 
substantially modify the relationships 
between the five drugs and DM, although 
the relationship with stavudine  was  
reduced  from 1.19 to 1.13. 
 
CONCLUSIONS 
Our results show a significant 
relationship between new onset DM and 
exposure to cART, this effect being mainly 
related to exposure to stavudine, but 
exposure to zidovudine and didanosine were 
also associated with an increased risk , 
whereas exposure to ritonavir and 
nevirapine were both associated with a 
reduced risk of DM. This is Our findings are  
consistent with  two other cohort studies  
which showed a similar relationship 
between exposure to stavudine and 
incidence of DM  (2,3). We found  a lower 
incidence of new onset DM than in the 
Multicenter AIDS Cohort Study (MACS) - 
5.72 per 1000 PYFU, versus 47 and 17 per 
1000 PYFU among individuals with or 
without cART  (2).  This difference could 
be related to different size and demographic 
compositions of both cohorts - the MACS 
involved exclusively white males  likely to 
be exposed to the typical North American 
diet,  older and with  a higher BMI than 
D:A:D  participants. In addition, in the 
MACS a single elevated fasting blood 
glucose was sufficient to establish a 
diagnosis of DM, a less stringent criterium 
than used in our study.  Importantly, in the 
MACS, fasting glucose levels were obtained 
as part of the assessments at predefined 
cohort visits, whereas in our cohort the 
validation of DM as an endpoint is 
dependent on the actual screening policy for 
glucose intolerance and DM which is in 
place in each of the 212 treatment units 
contributing data to D:A:D,  which 
undoubtedly differs between centers. 
The association between DM/insulin 
resistance and stavudine/zidovudine might 
be explained through an indirect 
mechanism, i.e lipoatrophy which is a state 
which is associated with insulin resistance.  
The increased lipolysis observed in patients 
with lipoatrophy actually reflects their 
adipose tissue being insulin resistant. 
Lipolysis leads to increased circulating free 
fatty acids which may reinforce insulin 
resistance in the liver and skeletal muscles 
(4). 
However, clinical evidence for a direct 
effect of thymidine analogues nucleoside 
reverse transcriptase inhibitors (NRTIs) on 
insulin sensitivity is also emerging.  ART-
naïve subjects randomized to stavudine- and 
didanosine-based therapy had a significant 
increase in HOMA-IR at 1 month while 
there was no change in those randomized to 
abacavir and lamivudine (5).  Exposure to 
stavudine and didanosine  is associated with 
greater lipoatrophy, illustrating the link 
between drug-related lipoatrophy and 
insulin resistance (2-6). Stavudine exposure 
leads to depletion of mitochondrial DNA 
content which may result in mitochondrial 
dysfunction.  A recent study performed in 
healthy volunteers demonstrated that a one-
month exposure to stavudine reduces insulin 
sensitivity in parallel with a 58% reduction 
in muscle mitochondrial DNA suggesting 
that mitochondrial dysfunction and insulin 
sensitivity were linked (7). Several studies 
have shown that  Data in HIV uninfected 
individuals have suggested that 
mitochondrial dysfunction precedes the 
onset of DM in insulin resistant offspring of 
patients with type 2 DM. Alterations of 
several genes involved in mitochondrial 
oxidative phosphorylation have been 
identified in muscle samples of patients with 
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type 2 DM and impaired glucose tolerance 
(8-10).  
The other risk factors for DM identified 
in our study included male sex, older age, 
greater BMI and black race, largely 
consistent with other studies in both the 
HIV-uninfected and HIV-infected 
populations (11). Current smoking status 
appeared to be marginally protective, 
contradicting some studies but consistent 
with results from the MRFIT trial of 
interventions for the reduction of CVD (12). 
The lower incidence of DM in recent 
calendar years could be inherent to the study 
design, i.e. follow up of a closed cohort 
where the patients at risk (i.e. susceptible to 
develop an end point) experience this 
relatively soon after enrolment reducing the 
subsequent risk in the cohort. It is also 
possible that the movement away from 
“old” drugs, particularly stavudine, towards 
alternative agents which are not associated 
with lipoatrophy development and have less 
or no effect on mitochondria may partially 
explain this finding.  
Our data do not show a significant 
relationship between cumulative exposure to 
PIs and new onset DM. This is in line with a 
recent study in PI-exposed women which 
showed  that cumulative exposure to PI was 
not associared with incidence of DM while 
cumulative exposure to NRTI was. (3) 
Antiretroviral regimens that include PIs for 
the treatment of HIV-1 have been associated 
with new-onset DM and insulin resistance 
(13-14 ). Reversal of hyperglycemia after PI 
withdrawal, onset of hyperinsulinemia 
before measurable body composition 
changes in PI recipients, and improvements 
in insulin sensitivity after substitution of PIs 
by the NNRTI nevirapine or the NRTI 
abacavir all suggest a direct effect of PIs on 
reducing insulin sensitivity in HIV-infected 
patients (15-16 ). In our study, we focused 
on the cumulative effect of exposure to 
antiretroviral drugs.  Data from other studies 
suggest that the effect of indinavir on 
insulin resistance is of acute onset rather 
than  cumulative or long term effect, and  
that this effect is reversible following drug 
discontinuation  The acute effect seen with 
indinavir in human volunteers on insulin 
resistance is limited in size and no way in 
order of magnitude of the relationship seen 
with lipodystrophy.  The Swiss HIV Cohort 
Study recently showed that new onset DM 
was independently associated with current 
exposure to indinavir, lamivudine-
stavudine, didanosine-stavudine and 
didanodine-tenofovir; other PI and NRTI 
also showed trends (17 ). In a preliminary 
analysis we tested whether current use of 
indinavir or other PIs were associated with 
the risk of developing DM, which did 
suggest that current indinavir exposure was 
an additional risk factor for DM in our 
dataset. Additional analyses are planned to 
quantify this effect.  The apparent slightly 
protective effect of ritonavir should be 
viewed cautiously; it could reflect the 
increasing use of more recent ritonavir-
boosted PI regimens with less impact on 
insulin sensitivity. 
Total cholesterol, HDL cholesterol and 
triglycerides were all associated with new 
onset DM after adjustment for demographic 
and clinical factors as well as for stavudine 
exposure, but adjusting for lipid parameters 
only slightly reduced the relationship 
between stavudine and DM. This 
relationship could be due to a common 
pathophysiologic mechanism leading to 
both lipid disorders and DM. Alternatively, 
lipolysis and increased serum free fatty 
acids have been documented in HIV-
positive individuals. Excess free fatty acids 
in the circulation may reduce insulin 
sensitivity through inappropriate lipid 
storage in muscle and liver, resulting in 
impaired glucose utilization and insulin-
mediated inhibition of glucogenolysis and 
gluconeogenesis (6, 18-20 ). 
Clinically observed lipodystrophy was 
also significantly associated with new onset 
DM  in accordance with previous studies 
showing that abnormal body fat distribution 
in HIV-positive individuals is strongly 
associated with insulin resistance and/or 
glucose intolerance, excess trunk or visceral 
fat being, as in the general population , a 
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 7
risk factor for insulin resistance among 
those with HIV infection. In addition, 
insulin resistance is itself independently 
associated with fat loss in HIV-positive 
individuals (4, 21)  
Our data confirm previous findings on the 
relationship between new onset of DM and 
exposure to stavudine (but also zidovudine 
and didanosine), increased total cholesterol, 
decreased HDL cholesterol and increased 
triglycerides. Interestingly, relationships for 
those parameters remained significant after 
adjustment for all other available risk 
factors.  The large size of this cohort 
provides greater power to detect findings 
that other cohorts may be insufficiently 
powered to detect. However, it is possible 
that some of these results may reflect 
chance findings. There are several 
limitations of the study that should be 
considered: firstly, cohort studies such as 
ours cannot formally determine causality.  
However, they do permit an association 
between drug exposure and incidence of 
DM to be established and our findings are 
both consistent with other cohorts and 
biologically plausible. Secondly, factors 
such as treatment interruptions or changes in 
adherence are not taken into account  
because of the complex treatment patterns in 
this population.  Finally, whilst we 
recognize that standardized assessments of 
lipodystrophy would have been preferable, 
this is unrealistic to achieve in a large multi-
cohort collaboration such as this. 
The relationship between new onset DM 
and exposure to stavudine (and other 
NRTIs) and lipodystrophy is a striking 
finding, particularly as adjustment for 
lipodystrophy did not modify the 
relationship between stavudine and DM.  It 
is plausible that stavudine and other NRTIs 
directly contribute to insulin resistance and 
DM, apart from any indirect effect by way 
of lipodystrophy development.  It should 
also be noted that our binary categorization 
of lipodystrophy may provide a relatively 
blunt tool with which to perform statistical 
adjustment; adjustment for the degree to 
which lipodystrophy is present (rather than 
just its presence or absence) may explain a 
higher proportion of the effect of stavudine.  
However, this level of information on 
lipodystrophy is rarely collected. 
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TABLE 1. Characteristics of patients at enrolment in the D:A:D study 
 
  n (%) 
Number of patients included  32437 (100.0) 
Sex : Male 23945 (73.8) 
Age (years) Median (IQR) 38 (33-44) 
Mode of infection Homosexual 13931 (43.0) 
 Injecting drug use 5849 (18.0) 
 Heterosexual 9759 (30.1) 
 Other/not known 2898 (8.9) 
Race: White 14492 (44.7) 
 Black 3334 (10.3) 
 Other 952 (2.9) 
 Not known 13659 (42.1) 
Current smoker:  10885 (33.6) 
Ever smoked:  15620 (48.2) 
Body mass index (Kg/m²): Median (IQR) 23.0 (21.0-25.2) 
CD4 count at entry (cells/mm³): Median (IQR) 410 (250-600) 
Duration of injection (yrs): Median (IQR) 5.0 (1.6-9.8) 
Previous AIDS:  7832 (24.2) 
Treatment status et entry:    
    
Antiretroviral-naïve:  8778 (27.1) 
Use of any ARV :Median (IQR) exposure duration 3.1 (1.6,4.8) yrs  23660 (72,9%) 
Use of any PI : Median (IQR) exposure duration 2.3 1.2,3.2) yrs  18751 (57,8%) 
Use of any NNRTI: Median (IDR) exposure duration: 0.9 (0.4,1.6) yrs  10705 (33,0%) 
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TABLE 2. Results from multivariable analyses of demographic and clinical factors 
associated with new onset DM 
  Relative 
rate 
95% CI p-value 
Exposure to antiretroviral drugs (per yr)     
Stavudine  1.19 1.15-1.24 0.0001 
 Zidovudine 1.06 1.03-1.10 0.0004 
 Didanosine 1.06 1.02-1.11 0.01 
 Ritonavir 0.94 0.89-0.99 0.01 
 Nevirapine 0.89 0.84-0.95 0.0001 
Age (per 5 years)  1.28 1.24-1.32 0.0001 
Male sex  1.61 1.30-2.00 0.0001 
BMI <18 0.73 0.41-1.31  
 18-26 1 -  
 26-30 2.17 1.79-2.63  
 >30 4.47 3.53-5.67  
 Not known 1.18 0.95-1.46 0.0001 
Ethnicity White 1 -  
 Black 1.85 1.36-2.53  
 Other 1.87 1.21-2.88  
 Not know 1.28 0.75-2.19 0.0005 
Risk group Homosexual 1 -  
 Heterosexual 1.45 1.15-1.82  
 IDU 1.21 0.98-1.48  
 Other risk 1.10 0.83-1.44 0.02 
Smoking status Current smoker 0.76 0.62-0.93  
 Ex-smoker 0.98 0.79-1.20  
 Never smoker 1 -  
 Not known 0.90 0.67-1.20 0.04 
Year 199/2000 3.40 2.52-4.60  
 2001 2.60 1.96-3.45  
 2002 1.85 1.39-2.47  
 2003 2.22 1.69-2.91  
 2004 1.37 1.03-1.83  
 2005/6 1 - 0.0001 
 
* All results are also adjusted for all variables and for cohort 
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TABLE 3. Results from multivariable analyses* to assess the association between exposure 
to five antiretroviral drugs and new onset DM after adjusting for time-updated metabolic 
parameters** 
  Relative rate 95% CI p-value 
Exposure to antiretroviral drugs (per yr)     
Stavudine  1.13 1.08-1.15 0.0001 
 Zidovudine 1.05 1.01-1.10 0.01 
 Didanosine 1.06 1.01-1.11 0.02 
 Ritonavir 0.90 0.85-0.95 0.0001 
 Nevirapine 0.92 0.86-0.99 0.02 
HDL cholesterol (per mmol/L higher) 0.75 0.58-0.96 0.02 
Triglycerides (per log2 higher) 1.64 1.50-1.80 0.0001 
Fat loss  1.09 0.88-1.36 0.42 
Fat gain  1.36 1.09-1.68 0.006 
 
• Estimates also adjusted for all variables shown in Table 2 
• **Relationship with each drug was adjusted for all others. 
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•  
